Alendronate reduces periosteal microperfusion in vivo
Objectives: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reaction...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023066768 |
| _version_ | 1797669852844916736 |
|---|---|
| author | Danielle N. Kundert Frank Tavassol Andreas Kampmann Nils-Claudius Gellrich Daniel Lindhorst Marc M. Precht Paul Schumann |
| author_facet | Danielle N. Kundert Frank Tavassol Andreas Kampmann Nils-Claudius Gellrich Daniel Lindhorst Marc M. Precht Paul Schumann |
| author_sort | Danielle N. Kundert |
| collection | DOAJ |
| description | Objectives: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. Study design: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. Results: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm2, two weeks alendronate treatment 44.77 ± 3.55 cm/cm2, six weeks alendronate treatment 27.54 ± 2.23 cm/cm2) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. Conclusion: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ. |
| first_indexed | 2024-03-11T20:50:49Z |
| format | Article |
| id | doaj.art-9b0bd45674d04675a9951aa682e0f172 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-11T20:50:49Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-9b0bd45674d04675a9951aa682e0f1722023-10-01T05:59:46ZengElsevierHeliyon2405-84402023-09-0199e19468Alendronate reduces periosteal microperfusion in vivoDanielle N. Kundert0Frank Tavassol1Andreas Kampmann2Nils-Claudius Gellrich3Daniel Lindhorst4Marc M. Precht5Paul Schumann6Division of Cranio-Maxillo-Facial and Oral Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zürich, Switzerland; Corresponding author.Department of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, GermanyDepartment of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, GermanyDepartment of Oral and Maxillofacial Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, GermanyKieferchirurgie-Zentrum-Hamburg, Lerchenfeld 14, 22081, Hamburg, GermanyDivision of Cranio-Maxillo-Facial and Oral Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zürich, SwitzerlandDivision of Cranio-Maxillo-Facial and Oral Surgery, University Hospital Zurich, University of Zurich, Frauenklinikstrasse 24, 8091, Zürich, SwitzerlandObjectives: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate alendronate-induced microcirculatory reactions in the calvarial periosteum of rats. Study design: Bone chambers were implanted into 48 Lewis rats. Microhemodynamics, inflammatory parameters, functional capillary density and defect healing were examined after alendronate treatment for two and six weeks using repetitive intravital fluorescence microscopy for two weeks. Results: Microhemodynamics remained unchanged. In alendronate-treated rats, inflammation was slightly increased, functional capillary density was significantly reduced (day 10: controls 100.45 ± 5.38 cm/cm2, two weeks alendronate treatment 44.77 ± 3.55 cm/cm2, six weeks alendronate treatment 27.54 ± 2.23 cm/cm2) and defect healing was decelerated. The changes in functional capillary density and defect healing were dose-dependent. Conclusion: The bisphosphonate alendronate has a significant negative impact on periosteal microperfusion in vivo. This could be a promising target for the treatment of MRONJ.http://www.sciencedirect.com/science/article/pii/S2405844023066768BisphosphonatesMRONJMicrocirculationIntravital fluorescence microscopyLewis rats |
| spellingShingle | Danielle N. Kundert Frank Tavassol Andreas Kampmann Nils-Claudius Gellrich Daniel Lindhorst Marc M. Precht Paul Schumann Alendronate reduces periosteal microperfusion in vivo Heliyon Bisphosphonates MRONJ Microcirculation Intravital fluorescence microscopy Lewis rats |
| title | Alendronate reduces periosteal microperfusion in vivo |
| title_full | Alendronate reduces periosteal microperfusion in vivo |
| title_fullStr | Alendronate reduces periosteal microperfusion in vivo |
| title_full_unstemmed | Alendronate reduces periosteal microperfusion in vivo |
| title_short | Alendronate reduces periosteal microperfusion in vivo |
| title_sort | alendronate reduces periosteal microperfusion in vivo |
| topic | Bisphosphonates MRONJ Microcirculation Intravital fluorescence microscopy Lewis rats |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023066768 |
| work_keys_str_mv | AT daniellenkundert alendronatereducesperiostealmicroperfusioninvivo AT franktavassol alendronatereducesperiostealmicroperfusioninvivo AT andreaskampmann alendronatereducesperiostealmicroperfusioninvivo AT nilsclaudiusgellrich alendronatereducesperiostealmicroperfusioninvivo AT daniellindhorst alendronatereducesperiostealmicroperfusioninvivo AT marcmprecht alendronatereducesperiostealmicroperfusioninvivo AT paulschumann alendronatereducesperiostealmicroperfusioninvivo |